X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA CIPLA PLETHICO PHARMA/
CIPLA
 
P/E (TTM) x -1.1 37.7 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PLETHICO PHARMA   CIPLA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
CIPLA
Mar-17
PLETHICO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs395622 63.5%   
Low Rs31458 6.8%   
Sales per share (Unadj.) Rs604.4181.9 332.4%  
Earnings per share (Unadj.) Rs32.512.9 252.4%  
Cash flow per share (Unadj.) Rs51.329.3 175.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs473.6155.7 304.2%  
Shares outstanding (eoy) m34.08804.51 4.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.43.0 11.9%   
Avg P/E ratio x6.642.0 15.6%  
P/CF ratio (eoy) x4.218.4 22.5%  
Price / Book Value ratio x0.53.5 13.0%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m7,262434,516 1.7%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m1,59626,338 6.1%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m20,598146,302 14.1%  
Other income Rs m3862,287 16.9%   
Total revenues Rs m20,984148,589 14.1%   
Gross profit Rs m2,81824,758 11.4%  
Depreciation Rs m64213,229 4.9%   
Interest Rs m1,5931,594 100.0%   
Profit before tax Rs m96912,222 7.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,798 -7.7%   
Profit after tax Rs m1,10710,354 10.7%  
Gross profit margin %13.716.9 80.8%  
Effective tax rate %-14.314.7 -97.1%   
Net profit margin %5.47.1 75.9%  
BALANCE SHEET DATA
Current assets Rs m18,87787,370 21.6%   
Current liabilities Rs m11,89633,081 36.0%   
Net working cap to sales %33.937.1 91.3%  
Current ratio x1.62.6 60.1%  
Inventory Days Days3687 41.3%  
Debtors Days Days19862 317.5%  
Net fixed assets Rs m9,861111,567 8.8%   
Share capital Rs m3411,609 21.2%   
"Free" reserves Rs m12,331123,645 10.0%   
Net worth Rs m16,139125,254 12.9%   
Long term debt Rs m4,70636,454 12.9%   
Total assets Rs m33,146209,532 15.8%  
Interest coverage x1.68.7 18.5%   
Debt to equity ratio x0.30.3 100.2%  
Sales to assets ratio x0.60.7 89.0%   
Return on assets %8.15.7 142.9%  
Return on equity %6.98.3 83.0%  
Return on capital %12.38.5 144.6%  
Exports to sales %21.434.2 62.5%   
Imports to sales %15.28.3 182.5%   
Exports (fob) Rs m4,40250,050 8.8%   
Imports (cif) Rs m3,13612,203 25.7%   
Fx inflow Rs m4,40251,066 8.6%   
Fx outflow Rs m3,18417,678 18.0%   
Net fx Rs m1,21933,388 3.6%   
CASH FLOW
From Operations Rs m2,43723,824 10.2%  
From Investments Rs m-6,265-13,127 47.7%  
From Financial Activity Rs m2,490-13,239 -18.8%  
Net Cashflow Rs m-1,337-2,478 54.0%  

Share Holding

Indian Promoters % 82.7 16.0 516.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.3 12.2 35.2%  
FIIs % 5.5 23.7 23.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 7.5 26.2 28.6%  
Shareholders   10,665 161,166 6.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Drag(09:30 am)

Asian share markets slipped in the opening trade today as investors digested the escalation in trade tensions between the US and China after both countries announced tariffs last week.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - BIOCON LTD COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS